Pancreatic and multiorgan resection with inferior vena cava reconstruction for retroperitoneal leiomyosarcoma by Stauffer, John A et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
World Journal of Surgical Oncology
Open Access Case report
Pancreatic and multiorgan resection with inferior vena cava 
reconstruction for retroperitoneal leiomyosarcoma
John A Stauffer1, G Peter Fakhre1, Marjorie K Dougherty2, Raouf E Nakhleh3, 
William J Maples4 and Justin H Nguyen*2
Address: 1Section of General Surgery, Mayo Clinic, Jacksonville, Florida, USA, 2Division of Transplant Surgery, Mayo Clinic, Jacksonville, Florida, 
USA, 3Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA and 4Division of Hematology and Oncology 
(W.J.M.), Mayo Clinic, Jacksonville, Florida, USA
Email: John A Stauffer - stauffer.john@mayo.edu; G Peter Fakhre - fakhre.peter@mayo.edu; 
Marjorie K Dougherty - dougherty.marjorie@mayo.edu; Raouf E Nakhleh - not@valid.com; William J Maples - maples.william@mayo.edu; 
Justin H Nguyen* - nguyen.justin@mayo.edu
* Corresponding author    
Abstract
Background: Inferior vena cava (IVC) leiomyosarcoma is a rare tumor of smooth muscle origin.
It is often large by the time of diagnosis and may involve adjacent organs. A margin-free resection
may be curative, but the resection must involve the tumor en bloc with the affected segment of
vena cava and locally involved organs. IVC resection often requires vascular reconstruction, which
can be done with prosthetic graft.
Case presentation: We describe a 39-year-old man with an IVC leiomyosarcoma that involved
the adrenal gland, distal pancreas, and blood supply to the spleen and left kidney. Tumor excision
involved en bloc resection of all involved organs with reimplantation of the right renal vein and
reconstruction of the IVC with a polytetrafluoroethylene graft. The patient recovered without
renal insufficiency, graft infection, or other complications. Follow-up abdominal imaging at 1 year
showed a patent IVC graft and no locally recurrent tumor. Prosthetic graft provides a sufficient
diameter and length for replacement conduit in extensive resection of IVC leiomyosarcoma.
Conclusion:  To our knowledge, this is the first case of resection of an IVC sarcoma with
prosthetic graft reconstruction in combination with pancreatic resection. Aggressive surgical
resection including vascular reconstruction is warranted for select IVC tumors to achieve a
potentially curative outcome.
Background
Inferior vena cava (IVC) leiomyosarcomas are rare malig-
nancies; fewer than 300 have been reported in literature.
This mesenchymal tumor is derived from medial smooth
muscle cells and most often originates from the IVC seg-
ment between the hepatic veins and the renal veins [1]. It
is most commonly diagnosed in women in their sixth dec-
ade, and the tumors often reach large dimensions before
detection because of an absence of symptoms [2-6]. They
are slow-growing and potentially curable by complete and
margin-free resection but are well known to present diffi-
culties in resection because of their location and involve-
ment of surrounding organs and vascular structures.
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Locally involved organs are commonly the kidney, adre-
nal gland, and liver [2,3,5-8]. Radical resection of the
tumor en bloc with the affected segment of the vena cava
has been shown in multiple studies to be a feasible option
with improved survival [1-3,5,6,9,10]. The pancreas is not
often involved with this retroperitoneal sarcoma, and
pancreas resection may increase the risk of graft infection.
Indeed, to our knowledge, a concomitant retroperitoneal
sarcoma resection and pancreas resection with IVC inter-
position grafting have not been reported in literature. We
describe a patient with a leiomyosarcoma involving the
left kidney, left adrenal gland, and distal pancreas, which
required IVC resection followed by reconstruction with
polytetrafluoroethylene (PTFE).
Case presentation
A previously healthy 39-year-old man presented to the
emergency department with a 2-month history of inter-
mittent dull abdominal ache with weight gain as well as
intermittent right upper extremity numbness. Physical
examination revealed a mildly obese abdomen with a
subtle mass in the left upper quadrant. No lower extremity
edema was noted. Abdominal magnetic resonance imag-
ing revealed a 15 × 6 × 5-cm, well-circumscribed, preaortic
retroperitoneal mass, which involved the IVC, causing
mass effect on the surrounding organs (Figure 1a, b). The
mass was believed to originate from the IVC but was with-
out total IVC occlusion. Tumor involved the left renal
artery, splenic artery, and distal pancreas. Hemoglobin,
platelet, serum urea nitrogen, creatinine, liver function
test, α-fetoprotein, carcinoembryonic antigen, and CA 19-
9 findings were all within normal limits. Cells obtained by
computer tomographically guided needle biopsy stained
positive for vimentin and desmin, confirming the mass
was a high-grade retroperitoneal leiomyosarcoma. Further
imaging revealed metastatic involvement of the fifth cer-
vical vertebra and epidural membrane. Over the course of
the next 8 months, the patient underwent a C5 corpec-
tomy and fusion with removal of the epidural tumor for
his metastatic lesion and received 50.4 Gy intensity-mod-
ulated radiation therapy to his abdomen, 43.2 Gy to his
cervical spine, and 4 cycles of ifosfamide and doxorubicin
chemotherapy. Subsequent evaluation showed isolated
disease in the retroperitoneum, and the patient was con-
sidered to be a candidate for resection with IVC recon-
struction of his symptomatic primary tumor.
Surgical resection of the mass was performed through a
bilateral subcostal incision. Careful abdominal explora-
tion confirmed the preoperative findings, and no other
metastases were present. The tumor appeared to arise
from the IVC at the level of the left renal vein and extend
intraluminally in the IVC up to the caudate lobe, involv-
ing the left kidney, left adrenal gland, distal pancreas,
splenic artery, and left renal artery. The tumor was mobi-
lized en bloc with the left kidney, left adrenal gland, distal
pancreas, and spleen. Proximal and distal control of the
IVC was obtained, and the tumor was resected. The pan-
creas was transected with a linear stapling device, the
main pancreatic duct was identified and oversewn, and a
closed suction drain was placed at the transection site.
Adequate margins were ensured by frozen section. IVC
a, Magnetic resonance imaging shows the tumor (large asterisk) lying to the left of the superior mesenteric artery (SMA),  involving the distal pancreas anteriorly, the superior pole of the left kidney posteriorly, and extending into the inferior vena  cava (IVC) (small asterisk) Figure 1
a, Magnetic resonance imaging shows the tumor (large asterisk) lying to the left of the superior mesenteric 
artery (SMA), involving the distal pancreas anteriorly, the superior pole of the left kidney posteriorly, and 
extending into the inferior vena cava (IVC) (small asterisk). b, The tumor (large asterisk) involves and encases the left 
renal vein and extends into the IVC. SMA indicates superior mesenteric artery.World Journal of Surgical Oncology 2009, 7:3 http://www.wjso.com/content/7/1/3
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reconstruction was performed from the level of the cau-
date lobe to the distal IVC in an end-to-end fashion with
a 14-mm external ring-reinforced PTFE interposition graft
(Figure 2). The graft was wrapped with omentum and iso-
lated from the overlying viscera. The right renal vein was
reimplanted into the infrarenal IVC. Gross and his-
topathologic examination revealed high-grade leiomyosa-
rcoma originating from the IVC involving the adrenal
gland and pancreas (Figure 3). After the operation, the
patient's renal function remained intact, and he was dis-
charged from the hospital on postoperative day 17 on
low-dose oral anticoagulation for 3 months.
Postoperatively, the patient underwent adjuvant chemo-
therapy with 4 cycles of docetaxel and gemcitabine, resec-
tion of a metastatic left deltoid tumor mass, and 40.0 Gy
of radiation therapy to his left upper extremity. Follow-up
abdominal imaging at 1 year revealed no recurrent
abdominal disease and a patent IVC graft (Figure 4).
Discussion
Primary leiomyosarcoma of the IVC is a rare malignant
tumor first described in 1891 by Perl at autopsy. The most
common presenting symptoms are abdominal pain, pal-
pable abdominal mass, and lower limb edema [1]. How-
ever, even with extensive caval involvement, severe
venous obstructive symptoms are not often seen, proba-
bly because of the development of extensive venous col-
laterals, which maintain adequate flow around the level of
obstruction [2]. The segment of IVC between the renal
veins and the hepatic veins (level II or middle segment) is
the most commonly affected location for all primary vas-
cular tumors [3,5,6].
IVC leiomyosarcomas are relatively resistant to chemo-
therapy and radiotherapy, and complete resection of the
tumor is the only known method for a chance of cure. The
prognosis for leiomyosarcoma of the IVC treated medi-
cally is poor, with an average survival of less than 3
months [1]. However, in the past 2 decades, aggressive
surgical resection has yielded notable survival benefits,
even for patients with metastatic disease. While data are
confined to a relatively small number of patients, 5-year
survival rates have been shown to be as high as 31% to
53% [3,5-8,10] after complete resection of level II IVC lei-
omyosarcoma.
Early diagnosis is rare, and the tumors often invade sur-
rounding organs. The amount of vascular involvement by
the retroperitoneal tumor accounts for the high surgical
risk and technical difficulties seen during attempts at com-
plete resection. Accurate preoperative imaging to deter-
mine the extent of the tumor is essential for adequate
planning, and magnetic resonance imaging is the pre-
ferred modality.
Caval management after IVC resection is controversial.
Options include primary repair, autologous patching,
ligation, or reconstruction with prosthetic graft. Extensive
venous involvement and large tumor size often preclude
short segment resection with simple repair or patching.
Ligation of the IVC is favored by some and has been
shown to be well tolerated and generally safe, especially in
those with preoperative IVC thrombosis [1,3]. However,
there is a risk of late complications such as pain, swelling,
and skin breakdown from severe lower extremity edema.
Long-term anticoagulation may be necessary in these
patients. Suprarenal IVC tumor involvement treated with
IVC ligation can place a patient at serious risk for renal
insufficiency. Restoration of flow to the right renal vein by
reimplantation (or pelvic kidney autotransplantation) is
mandatory to maintain right kidney function, but
optional for the left renal vein because of the left kidney's
considerable collateral drainage through the adrenal, infe-
rior phrenic, gonadal, and paravertebral vessels [11].
Because of the considerable size of these tumors at diag-
nosis, wide retroperitoneal dissection is often necessary
for complete tumor resection, disrupting the preexisting
venous channels. This dissection negates any collateral
flow that achieved venous decompression preoperatively.
Long segments of tumor involvement of the IVC necessi-
tate ligation of a larger amount of lumbar veins that serve
as collaterals. Kieffer et al [5] used a proximal pressure
reading of 30 mm Hg or more in the IVC as an indication
for caval reconstruction and found reconstruction to be
necessary in most cases. PTFE is the most commonly used
prosthetic material and has been shown to be a suitable
replacement for the IVC with excellent long-term patency
The interposition polytetrafluoroethylene graft (asterisk) was  anastomosed superiorly to the inferior vena cava (IVC) just  below the liver, and inferior to the infrarenal IVC, the right  renal vein (RRV) was reimplanted into the native IVC Figure 2
The interposition polytetrafluoroethylene graft 
(asterisk) was anastomosed superiorly to the inferior 
vena cava (IVC) just below the liver, and inferior to 
the infrarenal IVC, the right renal vein (RRV) was 
reimplanted into the native IVC.World Journal of Surgical Oncology 2009, 7:3 http://www.wjso.com/content/7/1/3
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[5,6,8-10,12]. Infection and graft thrombosis are the 2
major complications of this type of reconstruction, but
both are rare. Graft thrombosis may or may not have any
clinical importance, and methods used to decrease its
incidence include the use of ring-reinforced PTFE to pre-
vent compression, short-term anticoagulation, and place-
ment of an arteriovenous fistula to augment flow [5].
Although increasing the complexity of the operation,
partial or total resection of locally involved organs is
necessary for complete tumor removal because progno-
sis is highly dependent on a tumor-free margin. Patients
with inadequate resections are at high risk for local
recurrence, causing death from a retroperitoneal sar-
coma [3]. Multivisceral resection, especially of enteric
organs, may make a surgeon hesitant to place autoge-
nous material for reconstruction. However, PTFE graft
infection after IVC replacement has been shown to be a
rare occurrence in several large series [5,6,8-10,12].
Measures to decrease risk of graft contamination include
routine perioperative intravenous antibiotics, antibiotic
irrigation of the abdomen, and coverage of the graft with
omentum for graft isolation. However, to our knowl-
edge, resection of the pancreas has not been reported in
combination with IVC resection and reconstruction.
Pancreatic fistula occurs in up to 23% to 26% of cases of
distal pancreatectomy for malignancy [13,14]. Pancre-
atic leak would have serious consequences in the face of
prosthetic vascular material in close proximity and could
result in catastrophic graft infection. Measures to prevent
pancreatic contamination of the graft should be under-
taken, including ensuring adequate distal pancreatic
stump closure and providing sufficient closed suction
drainage of the pancreatic bed.
a, Specimen contained tumor mass, left kidney, left adrenal gland, spleen, and distal pancreas Figure 3
a, Specimen contained tumor mass, left kidney, left adrenal gland, spleen, and distal pancreas. b, Leiomyosar-
coma is seen in the lumen of the vena cava. The vena cava wall is on the right. c, Tumor fills the bottom of the picture pushing 
into the adrenal gland seen at the top of the picture. d, Tumor has replaced a portion of the pancreas. A pancreatic islet com-
plex is marked (hematoxylin and eosin, original magnification × 20).World Journal of Surgical Oncology 2009, 7:3 http://www.wjso.com/content/7/1/3
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Conclusion
Although often not curative, aggressive surgical resection
combined with chemoradiotherapy has been definitively
shown to prolong survival in patients with IVC leiomy-
osarcomas. Vascular reconstruction is often required, and
prosthetic replacement of the IVC with PTFE has been
shown to be a safe option for retroperitoneal sarcomas.
Graft-related complications are low but may be increased
by tumor involvement of the pancreas. However, pancre-
atic involvement did not preclude resection in this case,
giving the patient the survival benefit of a margin-free rad-
ical en bloc resection.
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One-year follow-up magnetic resonance image shows patent  polytetrafluoroethylene graft (asterisk) and no local tumor  recurrence Figure 4
One-year follow-up magnetic resonance image shows 
patent polytetrafluoroethylene graft (asterisk) and 
no local tumor recurrence.